U.S. Trade Distributors Stock News

Pennant Group’s FY 2025 Earnings Set Up the Next Phase of the Story The Pennant Group (PNTG) closed FY 2025 with fourth quarter revenue of US$289.3 million and basic EPS of US$0.25, capping a trailing twelve month period where revenue reached US$947.7 million and EPS came in at US$0.86. Over the past six reported quarters, the company has seen revenue move from US$188.9 million in Q4 2024 to US$289.3 million in Q4 2025, while quarterly EPS ranged between US$0.17 and US$0.25. This leaves...

If you are looking at Benchmark Electronics and wondering whether the current share price reflects its true worth, this article will walk through the key pieces you need to weigh that question up. The stock most recently closed at US$59.18, with returns of 3.2% over 7 days, 20.8% over 30 days, 34.8% year to date, 52.0% over 1 year and 163.2% over 3 years, so valuation now sits front and center for many investors. Recent coverage has focused on Benchmark Electronics as an established...

The U.S. Supreme Court recently ruled that the former president lacked authority to impose certain emergency tariffs under the 1977 International Emergency Economic Powers Act, a case that involved Goodyear Tire & Rubber and more than 1,000 other businesses. In response, the former president imposed a temporary 10% tariff on all U.S. imports under a separate 1974 law, potentially reshaping cost structures and refund claims for companies like Goodyear. While some consumers may have hoped for...

In February 2026, Horace Mann Educators launched the no-cost Horace Mann Club, giving educators nationwide access to wellness partnerships, financial tools, classroom resources, professional development programs, and identity and credit protection through a single registration platform. This broad suite of benefits positions Horace Mann as more than an insurance provider, deepening its role in educators’ professional, financial, and personal well-being. We’ll now examine how expanding...

Why Boston Scientific’s latest quarter is getting fresh attention Boston Scientific (BSX) has quickly moved onto investors’ radar after reporting peer leading revenue growth with a mixed earnings outlook, while at the same time expanding its buyback program and appointing two seasoned executives to its Board. See our latest analysis for Boston Scientific. Even with the recent board additions and expanded buyback, Boston Scientific’s share price has pulled back, with a 30 day share price...

BigBear.ai Holdings, Inc. previously announced it would report fourth-quarter 2025 results on March 2, 2026, alongside the completed US$250 million acquisition of Ask Sage, a generative AI platform serving defense and intelligence customers, against a backdrop of expected earnings per share and revenue declines. While recent quarters have seen revenue pressure, BigBear.ai enters this earnings release with an expanded generative AI toolkit for national security and a contract backlog of...

Pebblebrook Hotel Trust (PEB) has wrapped up FY 2025 with Q4 revenue of US$349.0 million, a basic EPS loss of US$0.23, and trailing twelve month revenue of about US$1.5 billion alongside a full year basic EPS loss of US$0.90. This gives investors a clear view of where the top line stands in relation to still negative earnings. The company has reported quarterly revenue moving from US$404.5 million in Q3 2024 to US$349.0 million in Q4 2025, while quarterly basic EPS has ranged from a loss of...

If you are wondering whether Atlanta Braves Holdings is fairly priced or trading at a premium, you are in the right place to unpack what the current share price might be telling you about value. The stock last closed at US$43.98, with reported returns of 2.5% over 7 days, 10.9% over 30 days, 10.3% year to date, 11.4% over 1 year and 50.1% over 5 years. These figures often prompt investors to reassess both upside potential and risk. Recent coverage around Atlanta Braves Holdings has focused...

The Baldwin Group recently announced a collaboration with Fairway Independent Mortgage Corporation to launch Fairway Home Insurance Agency, an affiliated platform that will use Baldwin’s technology, carrier relationships, and expertise to offer streamlined home and personal insurance solutions to mortgage clients nationwide starting in the second quarter of 2026. This embedded partnership extends Baldwin Insurance Group’s reach at the point of mortgage origination and home sale, reinforcing...

Sezzle (SEZL) just wrapped up FY 2025 with Q4 revenue of US$129.9 million and basic EPS of US$1.26, rounding out a trailing twelve months that delivered US$450.3 million in revenue and EPS of US$3.93. Over the past few quarters, the company has seen revenue move from US$69.96 million in Q3 2024 to US$98.22 million in Q4 2024, then to US$104.9 million in Q1 2025 and US$129.9 million in Q4 2025. Quarterly EPS shifted from US$0.46 in Q3 2024 to US$0.75 in Q4 2024 and climbed through 2025 to...

Commvault Systems (CVLT) is back in focus after unveiling a STACKIT partnership for EU sovereign cloud data protection and deepening its CrowdStrike integration. This has prompted fresh questions about how these developments could relate to the current share price. See our latest analysis for Commvault Systems. The STACKIT and CrowdStrike announcements arrive after a mixed period for the stock, with a 1-day share price return of 2.33% to US$88.58 but a 90-day share price return decline of...

With no single headline event driving attention today, Meta Platforms (META) is still on many investors’ radars as they reassess the stock after recent share price moves over the past month and the past 3 months. See our latest analysis for Meta Platforms. The recent 30 day share price return of a 2.37% decline contrasts with a small 1.01% year to date rise, while the three year total shareholder return of about 3x points to a very different long term picture. If this has you thinking about...

What Golar LNG’s Recent Performance Tells You Golar LNG (GLNG) has been quietly moving on the radar of income and infrastructure focused investors, with the stock showing mixed short term returns but stronger gains over the past 3 months and past year. At a recent close of $43.23, Golar LNG sits against a backdrop of annual revenue of $393.522 million and net income of $65.676 million, tied to its floating liquefied natural gas operations and related shipping and regasification...

Contract renewal in the Caspian Sea puts Helmerich & Payne in focus Turan Drilling and Engineering, a joint venture involving Helmerich & Payne (HP) and bp, has secured a 5 year offshore operations and maintenance contract renewal covering 8 platforms in the Caspian Sea. See our latest analysis for Helmerich & Payne. HP's recent 5 year Caspian contract renewal comes alongside a 90 day share price return of 23.98% and a 1 year total shareholder return of 37.05%. This suggests momentum has been...

Alnylam Pharmaceuticals (ALNY) has been drawing interest after recent trading, with the share price around $331.24 and mixed short term returns, including a 7 day decline and a positive 1 day move. See our latest analysis for Alnylam Pharmaceuticals. That short term pullback, including a 6.6% 30 day share price return decline and a 26.6% 90 day share price return decline, sits against a much stronger backdrop. The 1 year total shareholder return is 39.7% and the 5 year total shareholder...

Stock performance snapshot and business context NIQ Global Intelligence (NIQ) has drawn attention after a recent 4.9% gain in a single session and an 8.4% move over the past week, following a weaker month and past 3 months. The company focuses on consumer intelligence through AI powered software and analytics that aggregate and enrich shopping data, giving consumer brands and retailers an omnichannel view of behavior across products, channels, and media. With reported revenue of US$4.1b and a...

Celsius Holdings (CELH) closed out FY 2025 with Q4 revenue of US$721.6 million and basic EPS of US$0.04, alongside trailing twelve month revenue of about US$2.5 billion and EPS of US$0.25. This provides a clear snapshot of where the business stands after a volatile year. The company reported quarterly revenue of US$332.2 million in Q4 2024 and US$721.6 million in Q4 2025, while EPS moved from a loss of US$0.09 to a profit of US$0.04 over the same period. This sets up a results season in which...

In February 2026, Repligen Corporation reported that fourth-quarter 2025 revenue rose to US$197.91 million from US$167.55 million a year earlier, swinging from a net loss to net income of US$13.29 million and turning prior per-share losses into positive earnings. Alongside this stronger profitability, the company issued relatively cautious 2026 guidance for revenue of US$810 million to US$840 million and diluted earnings per share of US$1.93 to US$2.01, which contrasted with its recent...

IDEXX Laboratories (NasdaqGS:IDXX) announced the upcoming retirement of long-serving Board member M. Anne Szostak. The company also disclosed the appointment of Michael G. Erickson, PhD, to its Board of Directors. These Board changes reflect an ongoing refresh of corporate governance and Board composition. IDEXX Laboratories focuses on diagnostic and software solutions for veterinary practices, livestock, poultry, and water testing, placing the company at the center of long term trends in...

If you are wondering whether Bilibili’s current share price lines up with its underlying worth, you are not alone. This article will walk through what the numbers actually say about value. Bilibili’s stock has been volatile, with a 7 day return of an 8% decline, a 30 day return of a 17.9% decline, but a 1 year return of 37.5% and a 3 year return of 32.0%. This gives mixed signals about how the market is currently pricing the business. Recent headlines around Bilibili have focused on its...

If you are wondering whether AbbVie’s current share price lines up with its underlying worth, you are not alone. This article is built to help you unpack that question clearly. AbbVie recently closed at US$224.69, with returns of 0.2% over the last week, 0.3% over the last month, a 2.0% decline year to date, and 13.3% over the past year, alongside longer term returns of 62.2% over 3 years and 157.5% over 5 years. Recent coverage around AbbVie has focused on its position as a large...

Vaxcyte stock overview after recent price move Vaxcyte (PCVX) has drawn fresh attention after its recent share move, with the stock last closing at $60. For investors, the key question is how this price lines up with the company’s current fundamentals. See our latest analysis for Vaxcyte. That latest move to $60 comes after a choppy stretch, with a 1 day share price return of a 4.82% decline but a 90 day share price return of 20.94%, while the 1 year total shareholder return sits at a 19.16%...

If you are wondering whether Silicon Motion Technology is offering good value at its current price, you are not alone. The stock has drawn attention from investors trying to work out what a fair price really looks like. The share price closed at US$131.08 recently, with a 0.9% decline over the last 7 days but gains of 12.8% over 30 days, 39.8% year to date, 144.4% over 1 year, 109.4% over 3 years and 154.3% over 5 years. Those moves have kept the company on many investors' watchlists,...

AbCellera Biologics (ABCL) has drawn fresh attention after reporting a narrower quarterly loss than anticipated, supported by a substantial patent litigation settlement that lifted liquidity and coincided with progress across its clinical programs and manufacturing build out. See our latest analysis for AbCellera Biologics. The strong 1 day share price return of 12.54% and 7 day share price return of 11.49% around the results suggest investors are reassessing AbCellera’s risks and prospects...